Clinical Trial Search

Primary: Number of Participants With Antigen-specific Interferon- Secretion as Measured by Enzyme-linked Immunospot (ELISPOT) Assay — 4 participants

Primary: PSA Response, as Defined by ≥ 50% Decrease in PSA From Baseline — 1 Participants

Primary: Assesment of Serum Zinc/PSA Ratio in Patients With Prostate Cancer and Benign Prostatic Diseases — 150.8; 239.6 ratio

Primary: Association of PCA3 Score With Prostate Biopsy Outcome (PCA3 Score Using Cutoff of 25.) — 466; 102; 364; 235 participants

Primary: PET Detection of Primary Prostate Cancer — 6; 7 Participants

Primary: Prostate Cancer Detection Within the Prostate Gland by Copper Cu 64 TP3805 PET — 25 Participants

Primary: Proportion of Subjects With a Demethylation Response at Each Dose Level — .22; .30 proportion of participants

Primary: Number of Participants With an Immune Response — 2; 4; 4; 3 Participants

Primary: Tumor Growth Rate as Measured by Prostate-specific Antigen (PSA) Rise After 6 Months When PROSTVAC is Initiated Compared to a Group on Surveillance for 6 Months…

Primary: Response Rate (Progression) for Patients With Glioblastoma That Have Progressed After Prior Treatment That Has Included Radiation, Temozolomide and Bevacizumab. — 6…

Primary: Change in CD8+ Positive Cells in the Stroma Adjacent to Tumor and Within the Malignant Portion of the Prostate Biopsies — 12.2; -6.9 number of positive cells per mm^2

Primary: The Proportion of Men With a Positive MRI Defined by a Score of 3 or Greater — 17.7 Percentage of participants

Primary: Number of Prostate Cancer Diagnoses in MRI and no MRI Groups — 34; 34 participants

Primary: Number of Participants With a Positive Immune Response Following Vaccination Determined by Interferon (IFN) Gamma Enzyme-linked Immunosorbent Spot (ELISpot) — 12; 10…

Primary: Sensitivity of PSMA-PET and MRI Imaging Preoperatively for Predicting Extra-prostatic Extension — 86; 57 percentage — p=<0.05

Primary: True Positive Rate for Detection of Tumor Location in Lymph Nodes Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up

Primary: Number of Primary Prostate Lesions Detected on Early Dynamic 68Ga-PSMA-11 PET/CT Imaging — 24 lesions

Primary: Proportion of Patients With Lymph Node Involvement — 4; 28 Participants

Primary: Diagnostic Accuracy of PSMA PET — 100; 74 percentage

Primary: Sensitivity of Ga-68 HBED-CC PSMA for Detection of Nodal Metastases — .59; .89 proportion of participants

Primary: PCA3 Score Expressed as a Ratio of PCA3 mRNA (Messenger Ribonucleic Acid) Over PSA (Prostate Specific Antigen) mRNA — 232; 27; 10; 24 participants

Primary: The Number of Subjects With PSMA-positive (Prostate-specific Membrane Antigen) "Dominant" PC Lesion(s) Greater Than 5mm in Diameter, Whose Lesion(s) Have Been…

Primary: Prostate-specific Antigen (PSA) — 0.8; 0.9; 0.7; 0.4 ng/mL

Primary: Number of Participants With Any Grade or High Grade (Gleason Score 7 or Higher) Prostate Cancer as Measured by Histopathology — 11; 8 Participants

Primary: Number of Participants With Clinically Significant Prostate Cancer — 6; 6 Participants

Primary: Positive Predictive Value (PPV) on a Per-patient Basis With Histologic Validation — 0.90 percentage of times value is true

Primary: Sensitivity of Ga 68-labeled PSMA-11 Positron Emission Tomography/Computed Tomography (PET/CT) for the Detection on a Per Patient Basis — 1.0 proportion of participants

Primary: Number of Patients With PSA Response, Defined as a 50% or Greater Decline in the Serum PSA Level — 0; 28; 4; 3 participants

Primary: Percentage of Participants With Histologically Positive Lesions That Are Positive on Imaging — 86 % of participants with + lesions

Primary: Detection Rate of PSMA-11 PET for Positive Disease by Prostate Specific Antigen (PSA) Group — 0.38; 0.45; 0.76; 0.73 proportion